Home » Stocks » Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (TTNP)

Stock Price: $0.309 USD 0.009 (3.13%)
Updated Aug 10, 2020 2:04 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 29.60M
Revenue (ttm) 4.00M
Net Income (ttm) -17.53M
Shares Out 95.66M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $0.309
Previous Close $0.300
Change ($) 0.009
Change (%) 3.13%
Day's Open 0.304
Day's Range 0.297 - 0.318
Day's Volume 4,921,605
52-Week Range 0.142 - 0.789

More Stats

Market Cap 29.60M
Enterprise Value 26.08M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 95.66M
Float 95.38M
EPS (basic) -0.46
EPS (diluted) -0.44
FCF / Share -0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.67M
Short Ratio 0.67
Short % of Float 7.77%
Beta 0.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.40
PB Ratio 5.45
Revenue 4.00M
Operating Income -16.79M
Net Income -17.53M
Free Cash Flow -16.59M
Net Cash 3.51M
Net Cash / Share 0.04
Gross Margin -122.91%
Operating Margin -419.42%
Profit Margin -437.90%
FCF Margin -414.57%
ROA -84.94%
ROE -420.72%
ROIC -324.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$0.90*
(190.89% upside)
Low
0.80
Current: $0.309
High
1.00
Target: 0.90
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.616.620.2215.071.673.6510.487.124.0710.09
Revenue Growth-45.44%2978.14%-98.57%801.56%-54.17%-65.21%47.27%74.95%-59.69%-
Gross Profit2.326.080.2215.071.673.6510.487.124.0710.09
Operating Income-16.84-8.26-14.504.34-6.76-3.48-0.89-8.37-10.51-6.03
Net Income-16.46-9.02-14.315.14-11.28-2.409.71-15.18-15.20-6.83
Shares Outstanding22.965.693.533.463.342.842.492.011.791.79
Earnings Per Share-0.72-1.66-4.221.20-3.36-1.203.18-7.62-9.28-2.98
Operating Cash Flow-15.45-8.43-12.686.29-7.47-5.87-9.801.83-14.48-4.66
Capital Expenditures-0.26-0.42-0.18-0.17-0.13-0.02-0.32-1.15-0.23-0.03
Free Cash Flow-15.70-8.85-12.856.12-7.60-5.88-10.120.68-14.71-4.69
Cash & Equivalents5.229.667.8814.017.8615.4711.8018.105.413.18
Total Debt4.444.316.58----11.8612.257.27
Net Cash / Debt0.785.341.3014.017.8615.4711.806.24-6.85-4.09
Assets9.5214.108.9118.6713.2920.8518.4224.8310.224.75
Liabilities8.097.268.055.486.3012.2412.6647.9630.3010.81
Book Value1.436.830.8613.196.998.615.76-23.13-20.08-6.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Titan Pharmaceuticals, Inc.
Country United States
Employees 21
CEO Sunil Bhonsle

Stock Information

Ticker Symbol TTNP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TTNP
IPO Date January 18, 1996

Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction in patients. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.